News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,894 Results
Type
Article (39143)
Company Profile (283)
Press Release (648468)
Section
Business (203900)
Career Advice (1996)
Deals (35371)
Drug Delivery (89)
Drug Development (80846)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344638)
Policy (32450)
Tag
Academia (2530)
Alliances (49183)
Alzheimer's disease (1257)
Approvals (16049)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64692)
Collaboration (482)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6170)
Earnings (84892)
Employer resources (146)
Events (110005)
Executive appointments (394)
FDA (16767)
Funding (426)
Gene therapy (195)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16339)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (183)
Patents (117)
People (56455)
Phase I (20119)
Phase II (28493)
Phase III (21237)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21664)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15141)
Vaccines (563)
Weight loss (181)
Date
Today (31)
Last 7 days (580)
Last 30 days (2410)
Last 365 days (35198)
2024 (35002)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37266)
Australia (6087)
California (3809)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79824)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1460)
Texas (547)
Utah (108)
Washington State (399)
687,894 Results for "genprex inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
Genprex, Inc. today announced that it has issued a stockholder letter and corporate update summarizing the Company’s recent achievements across its clinical development programs and outlines key milestones for 2024 and beyond.
June 27, 2024
·
6 min read
Lone Star Bio
Genprex to Present at the 2024 BIO International Convention
Genprex, Inc. , today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.
May 30, 2024
·
5 min read
Press Releases
Genprex to Participate in 2024 BIO Europe Conference
October 31, 2024
·
5 min read
Lone Star Bio
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
Genprex, Inc. today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024.
May 1, 2024
·
5 min read
Business
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
Genprex, Inc. today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company’s co-founder and previous Chairman Rodney Varner.
May 13, 2024
·
6 min read
Business
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced with great respect and sorrow the unexpected passing last night of the Company’s co-founder, President, Chairman and Chief Executive Officer, Rodney Varner, due to sudden complications after a courageous battle with cancer.
May 8, 2024
·
7 min read
Press Releases
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
November 6, 2024
·
8 min read
Press Releases
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
December 16, 2024
·
9 min read
Lone Star Bio
Genprex to Present at Upcoming BIO CEO & Investor Conference
Genprex, Inc. today announced that its Chief Financial Officer, Ryan Confer will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming BIO CEO & Investor Conference.
February 6, 2024
·
5 min read
Deals
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex, Inc. today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock.
March 19, 2024
·
5 min read
1 of 68,790
Next
